AUDENTES THERAPEUTICS INC's ticker is BOLD and the CUSIP is 05070R104. A total of 193 filers reported holding AUDENTES THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 5.36 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $1,983,000 | -45.1% | 33,155 | -74.2% | 0.00% | -66.7% |
| Q3 2019 | $3,610,000 | -15.1% | 128,593 | +14.4% | 0.00% | +50.0% |
| Q2 2019 | $4,251,000 | +457.1% | 112,372 | +472.5% | 0.00% | – |
| Q1 2019 | $763,000 | -75.4% | 19,628 | -86.5% | 0.00% | -100.0% |
| Q4 2018 | $3,097,000 | -58.3% | 145,324 | -22.6% | 0.00% | 0.0% |
| Q3 2018 | $7,435,000 | +40.8% | 187,816 | +35.9% | 0.00% | 0.0% |
| Q2 2018 | $5,281,000 | +63.4% | 138,249 | +28.5% | 0.00% | 0.0% |
| Q1 2018 | $3,231,000 | +104.2% | 107,599 | +112.4% | 0.00% | +100.0% |
| Q4 2017 | $1,582,000 | +267.1% | 50,650 | +227.9% | 0.00% | – |
| Q3 2017 | $431,000 | +12.8% | 15,449 | -23.0% | 0.00% | – |
| Q2 2017 | $382,000 | +1428.0% | 20,057 | +1170.2% | 0.00% | – |
| Q1 2017 | $25,000 | -64.8% | 1,579 | -60.6% | 0.00% | – |
| Q4 2016 | $71,000 | +317.6% | 4,007 | +316.5% | 0.00% | – |
| Q3 2016 | $17,000 | – | 962 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 1,204,615 | $37,644,219,000 | 39.61% |
| Casdin Capital, LLC | 400,000 | $12,500,000 | 3.04% |
| Opaleye Management Inc. | 210,000 | $6,652,000 | 2.13% |
| Orbimed Advisors | 4,129,638 | $129,051,000 | 1.63% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,190,516 | $37,204,000 | 1.46% |
| Redmile Group, LLC | 929,326 | $29,041,000 | 1.26% |
| Cormorant Asset Management, LP | 337,876 | $10,559,000 | 1.10% |
| Perceptive Advisors | 781,309 | $24,416,000 | 0.81% |
| Rock Springs Capital Management LP | 525,000 | $16,406,000 | 0.74% |
| Virtus ETF Advisers LLC | 11,898 | $372,000 | 0.47% |